Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries

Bulletin of the World Health Organization

Volumn 76, Issue 1, 1998, Pages 25-32

  Berman, J D ^a   Badaro, R ^b   Thakur, C P ^c   Wasunna, K M ^d   Behbehani, K ^e   Davidson, R ^f   Kuzoe, F ^e   Pang, L ^g   Weerasuriya, K ^h   Bryceson, A D M ⁱ  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Balaji Utthan Sansthan   (India)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f NORTHWICK PARK HOSPITAL   (United Kingdom)

^g ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^h UNIVERSITY OF COLOMBO   (Sri Lanka)

ⁱ HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHILD; CHILL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEVER; HEART ARRHYTHMIA; HUMAN; INDIA; INTRAVENOUS DRUG ADMINISTRATION; KENYA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RESPIRATORY DISTRESS; VISCERAL LEISHMANIASIS;

AFRICA; AFRICA SOUTH OF THE SAHARA; AMERICAS; ASIA; BRAZIL; CLINICAL RESEARCH; DEVELOPING COUNTRIES; DISEASES; DRUGS--ADMINISTRACTION AND DOSAGE; DRUGS--SIDE EFFECTS; EASTERN AFRICA; ENGLISH SPEAKING AFRICA; HEALTH; INDIA; KENYA; LATIN AMERICA; LEISHMANIASIS--PREVENTION AND CONTROL; PARASITIC DISEASES; PUBLIC HEALTH; RESEARCH METHODOLOGY; RESEARCH REPORT; SAFETY; SOUTH AMERICA; SOUTHERN ASIA; TREATMENT;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BRAZIL; CHILD; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDEMIC DISEASES; HUMANS; INDIA; KENYA; LEISHMANIASIS, VISCERAL; TREATMENT OUTCOME;

EID: 17544387144     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Seaman J et al. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Annals of internal medicine, 1996, 124: 664-672.
2. Franke ED et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Annals of internal medicine, 1990, 113: 934-940.
3. Gasser RA et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clinical infectious diseases, 1994, 18: 83-90.
4. Franke ED et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. American journal of tropical medicine and hygiene, 1994, 51: 77-82.
5. Berman JD et al. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Molecular biochemical parasitology, 1986, 20: 85-92.
6. Thakur CP et al. Evaluation of amphotericin B as a first-line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian journal of medical research (A), 1993, 97: 170-175.
7. Thakur CP et al. Daily vs alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bulletin of the World Health Organization, 1994, 72: 931-936.
8. Thakur CP. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. National medical journal of India, 1995, 8: 13-14.
9. Mishra M et al. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet, 1994, 344: 1599-1600.
10. Mishra M et al. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet, 1992, 340: 1256-1257.
11. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clinical infectious diseases, 1996, 22 (suppl. 2): S133-S144.
12. Davidson RN et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet, 1991 337: 1061-1062.
13. Davidson RN et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-center trial. Quarterly journal of medicine 1994, 87: 75-81.
14. Thakur CP et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90: 319-322.
15. Chulay JD, Bryceson ADM. Quantification of amastigotes of Leishmania donovani in smear of splenic aspirates of patients with visceral leishmaniasis. American journal of tropical medicine and hygiene, 1983, 32: 474-479.
16. Davidson RN et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clinical infectious diseases, 1996, 22: 938-943.
17. Russo R et al. Visceral leishmaniasis in HIV-infected patients: treatment with high-dose liposomal amphotericin B (AmBisome). Journal of infection, 1996, 32: 133-137.
18. Levine SJ et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Annals of internal medicine, 1991, 114: 664-666.
19. Hardie WD et al. Effect of cyclooxygenase inhibition on amphotericin-B-induced lung injury in awake sheep. Journal of infectious diseases, 1992, 166: 134-138.